{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:01:37Z","timestamp":1789704097064,"version":"4.0.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.jaad.2016.10.033","type":"journal-article","created":{"date-parts":[[2016,12,28]],"date-time":"2016-12-28T01:47:04Z","timestamp":1482889624000},"page":"662-669.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Biologic drug survival in Israeli psoriasis patients"],"prefix":"10.1016","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3211-0023","authenticated-orcid":false,"given":"Guy","family":"Shalom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnon D.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ziv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cohen Barak","family":"Eran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilan","family":"Feldhamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar","family":"Freud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eitan","family":"Berman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley","family":"Oren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmilia","family":"Hodak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lev","family":"Pavlovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jaad.2016.10.033_bib1","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1038\/jid.2015.171","article-title":"Drug survival studies in dermatology: principles, purposes, and pitfalls","volume":"135","author":"van den Reek","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2016.10.033_bib2","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/bjd.12422","article-title":"Survival rate of\u00a0Anti-TNF alpha treatments for psoriasis in routine dermatological practice: a multicenter observational study","volume":"169","author":"Esposito","year":"2013","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2016.10.033_bib3","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1468-3083.2007.02425.x","article-title":"Adherence to treatment in patients with psoriasis vulgaris: Turkish experience","volume":"22","author":"Gokdemir","year":"2008","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jaad.2016.10.033_bib4","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1345\/aph.1E398","article-title":"Cost effectiveness of adherence-enhancing interventions: a qualitative assessment of the evidence","volume":"39","author":"Elliott","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jaad.2016.10.033_bib5","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N Engl J\u00a0Med"},{"key":"10.1016\/j.jaad.2016.10.033_bib6","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1111\/j.1365-2133.2011.10213.x","article-title":"Comparison of drug survival rates for adalimumab, etanercept, and infliximab in patients with psoriasis vulgaris","volume":"164","author":"Gniadecki","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.10.033_bib7","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1365-2133.2011.10557.x","article-title":"Drug survival rates of\u00a0biologic treatments in patients with psoriasis vulgaris","volume":"166","author":"Brunasso","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.10.033_bib8","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/bjd.13343","article-title":"Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris","volume":"172","author":"Gniadecki","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.10.033_bib9","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/1346-8138.12353","article-title":"Drug survival rates in patients with psoriasis after treatment with biologics","volume":"40","author":"Umezawa","year":"2013","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jaad.2016.10.033_bib10","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/bjd.13001","article-title":"Drug survival not significantly different among biologics in patients with psoriasis vulgaris: a single center database analysis","volume":"171","author":"Menting","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.10.033_bib11","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/jdv.12636","article-title":"Predictors of adalimumab drug survival in psoriasis differ by reason for discontinuation: long-term results from the Bio-CAPTURE Registry","volume":"29","author":"van den Reek","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2016.10.033_bib12","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1038\/jid.2015.208","article-title":"Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)","volume":"135","author":"Warren","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2016.10.033_bib13","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jaad.2015.12.017","article-title":"Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: results of a large prospective observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR])","volume":"74","author":"Strober","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.10.033_bib14","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.jaad.2016.01.037","article-title":"ORBIT (Outcome and Retention rate of BIologic Treatments for psoriasis): a retrospective observational study on biologic drug survival in daily practice","volume":"74","author":"Vilarrasa","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.10.033_bib15","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/bjd.14552","volume":"175","author":"Zweegers","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.10.033_bib16","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/bjd.14545","article-title":"Glycemic control in\u00a0patients with diabetes and concomitant psoriasis","volume":"175","author":"Shalom","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.10.033_bib17","doi-asserted-by":"crossref","first-page":"973","DOI":"10.2340\/00015555-2130","article-title":"Factors associated with drug survival of methotrexate and acitretin in patients with psoriasis","volume":"95","author":"Shalom","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2016.10.033_bib18","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1111\/jdv.12549","article-title":"Clinical relevance of immunogenicity of biologics in psoriasis: implications for treatment strategies","volume":"28","author":"Carrascosa","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2016.10.033_bib19","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1001\/archdermatol.2009.347","article-title":"Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis","volume":"146","author":"Lecluse","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2016.10.033_bib20","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40257-015-0131-y","article-title":"Immunogenicity of biologic treatments for psoriasis: therapeutic consequences and the potential value of concomitant methotrexate","volume":"16","author":"Farhangian","year":"2015","journal-title":"Am J Clin Dermatol"},{"issue":"Suppl 3","key":"10.1016\/j.jaad.2016.10.033_bib21","first-page":"S60","article-title":"Clinical impact of concomitant immunomodulators on biologic therapy: pharmacokinetics, immunogenicity, efficacy, and safety","volume":"55","author":"Xu","year":"2015","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.jaad.2016.10.033_bib22","doi-asserted-by":"crossref","first-page":"711","DOI":"10.2340\/00015555-2069","article-title":"Risk factor analysis for the immunogenicity of adalimumab associated with decreased clinical response in Chinese patients with psoriasis","volume":"95","author":"Chiu","year":"2015","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2016.10.033_bib23","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3899\/jrheum.140685","article-title":"Prevalence of\u00a0TNF-\u03b1 blocker immunogenicity in psoriatic arthritis","volume":"42","author":"Zisapel","year":"2015","journal-title":"J\u00a0Rheumatol"},{"issue":"2","key":"10.1016\/j.jaad.2016.10.033_bib24","first-page":"147","article-title":"Lower socioeconomic status is associated with decreased therapeutic response to the biologic agents in psoriasis patients","volume":"15","author":"Sorensen","year":"2016","journal-title":"J Drugs Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962216310088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962216310088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:40:43Z","timestamp":1759272043000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962216310088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0190962216310088"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2016.10.033","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologic drug survival in Israeli psoriasis patients","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2016.10.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}